Oxidized phospholipids (OxPL) are ubiquitous, are formed in many inflammatory tissues, including atherosclerotic lesions, and frequently mediate proinflammatory changes 1 . Because OxPL are mostly the products of non-enzymatic lipid peroxidation, mechanisms to specifically neutralize them are unavailable and their roles in vivo are largely unknown. We previously cloned the IgM natural antibody E06, which binds to the phosphocholine headgroup of OxPL, and blocks the uptake of oxidized low-density lipoprotein (OxLDL) by macrophages and inhibits the proinflammatory properties of OxPL 2-4 . Here, to determine the role of OxPL in vivo in the context of atherogenesis, we generated transgenic mice in the Ldlr −/− background that expressed a single-chain variable fragment of E06 (E06-scFv) using the Apoe promoter. E06-scFv was secreted into the plasma from the liver and macrophages, and achieved sufficient plasma levels to inhibit in vivo macrophage uptake of OxLDL and to prevent OxPL-induced inflammatory signalling. Compared to Ldlr −/− mice, Ldlr −/− E06-scFv mice had 57-28% less atherosclerosis after 4, 7 and even 12 months of 1% high-cholesterol diet. Echocardiographic and histologic evaluation of the aortic valves demonstrated that E06-scFv ameliorated the development of aortic valve gradients and decreased aortic valve calcification. Both cholesterol accumulation and in vivo uptake of OxLDL were decreased in peritoneal macrophages, and both peritoneal and aortic macrophages had a decreased inflammatory phenotype. Serum amyloid A was decreased by 32%, indicating decreased systemic inflammation, and hepatic steatosis and inflammation were also decreased. Finally, the E06-scFv prolonged life as measured over 15 months. Because the E06-scFv lacks the functional effects of an intact antibody other than the ability to bind OxPL and inhibit OxLDL uptake in macrophages, these data support a major proatherogenic role of OxLDL and demonstrate that OxPL are proinflammatory and proatherogenic, which E06 counteracts in vivo. These studies suggest that therapies inactivating OxPL may be beneficial for reducing generalized inflammation, including the progression of atherosclerosis, aortic stenosis and hepatic steatosis.
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of Ldlr −/− E06-scFv mice, consistent with either a plasma origin or local macrophage secretion (Extended Data Fig. 3d ).
To determine the effect of OxPL on atherosclerosis, Ldlr −/− and Ldlr −/− E06-scFv mice were fed a high-cholesterol diet (HCD) for 4, 7 or 12 months. Weight gain, plasma cholesterol, triglycerides and lipoprotein profiles were similar (Extended Data Table 1 and Extended Data Fig. 4 ). Compared to Ldlr −/− mice, atherosclerosis was significantly reduced in Ldlr −/− E06-scFv mice at each time point (per cent of aortic surface involved by en face analysis was reduced by 57%, 34% and 28%, and aortic root by 55%, 41% and 27%, respectively, at 4, 7 and 12 months; Fig. 2c, d) . OxPL have been shown to promote apoptosis and necrosis 1, 16 . In lesion size-matched cross-sections, necrotic core areas were 44% smaller (P = 0.015) and had visibly more collagen in Ldlr −/− E06-scFv mice, suggesting improved plaque stability (Extended Data Fig. 5a ).
The Apoe promoter is known to be active in macrophages and to respond to cholesterol and LXR agonists 17 . Peritoneal macrophages from Ldlr −/− E06-scFv mice expressed E06-scFv mRNA, and enzymelinked immunosorbent assay (ELISA) analysis of culture supernatants demonstrated the binding of secreted E06-scFv to phosphocholinebovine serum albumin (BSA) (Extended Data Fig. 5b ). The LXR agonist T0901317 enhanced synthesis and secretion of bioactive E06-scFv into the culture medium (Extended Data Fig. 5b ), demonstrating a functional Apoe promoter regulating expression of the E06-scFv in macrophages. To determine the contribution of macrophage E06-scFv to atherogenic protection, we performed a bone marrow transplantation (BMT) from C57BL/6 wild-type or from E06-scFv mice (not on Ldlr −/− background) into irradiated male Ldlr −/− recipients and fed the mice with a Western diet. Plasma E06-scFv titres were detectable in recipient Ldlr −/− mice two weeks after BMT and rose in response to cholesterol feeding (Extended Data Fig. 5c ), but even at 16 weeks were only around 10% of those observed in the Ldlr −/− E06-scFv mice. Nevertheless, aortic root lesions were reduced by 37% in mice receiving bone marrow from E06-scFv donors, compared to wild-type donors (Extended Data Fig. 5d ). Plasma lipids were not different (Extended Data Table 1 ). These data suggest an important role for local arterial macrophage secretion of E06-scFv in providing atheroprotection, although conceivably some of the benefits of E06-scFv could derive from macrophages engrafted in other tissues.
To provide insights into atheroprotective mechanisms, we demonstrated decreased in vivo macrophage uptake of fluorescently labelled OxLDL in Ldlr −/− E06-scFv mice. We used Rag1 −/− Ldlr −/− mice to exclude effects of other antibodies and allow an examination of the protective effect of the E06-scFv alone. Uptake of OxLDL was significantly reduced in macrophages of Rag1 −/− Ldlr −/− E06-scFv mice compared to Rag1 −/− Ldlr −/− mice (Fig. 3a) . To assess the full potential of E06-scFv to bind to OxLDL, we pre-incubated plasma from Ldlr −/− , Rag1 −/− Ldlr −/− or Rag1 −/− Ldlr −/− E06-scFv mice with the OxLDL before injection. Whereas macrophage uptake of OxLDL was approximately 100% or around 70% for OxLDL incubated with Rag1 −/− or Rag1 −/− Ldlr −/− plasma, respectively, it was reduced to around 26% when premixed with Rag1 −/− Ldlr −/− E06-scFv plasma (Fig. 3b) . Consistent with the decreased in vivo uptake of OxLDL, macrophage cholesterol content of Ldlr −/− E06-scFv mice was reduced by 48% compared to Ldlr −/− mice (P = 0.02; Fig. 3c ). Desmosterol was reported to be increased in macrophages from Western diet-fed Ldlr −/− mice, leading to decreased inflammatory gene expression 18 . However, neither desmosterol nor other oxysterol concentrations were different between macrophages of Ldlr −/− and Ldlr −/− E06-scFv mice (Extended Data Fig. 1f ).
RNA-sequencing analysis of TGEM ( Fig. 3d, e ) suggested a shift from a more inflammatory 'M1-like' phenotype in the Ldlr −/− mice to a more attenuated 'M2-like' repair phenotype in the Ldlr −/− E06-scFv mice. Gene Ontology analyses indicated that nearly all the genes expressed more than 1.5-fold higher in the Ldlr −/− E06-scFv macrophages relate to immune regulation and defence, of both innate and adaptive immune systems (Extended Data Table 2 ). We also used flow cytometry to profile arterial wall cells (Fig. 3f ). Compared to macrophages isolated Letter reSeArCH from aortas of chow-fed Ldlr −/− mice, macrophages from HCDfed Ldlr −/− mice were shifted to a predominant M1-like phenotype (CD45 + CD11b + CD11c + Arg1 − ), whereas despite the same cholesterol levels, macrophages from the HCD-fed Ldlr −/− E06-scFv mice showed an M2-like phenotype (CD45 + CD11b + CD11c − Arg1 + ), more comparable to the profile found in the chow-fed Ldlr −/− mice. Aortas from HCD-fed Ldlr −/− mice had greater total monocyte/ lymphocyte accumulation than did chow-fed Ldlr −/− or HCD-fed Ldlr −/− E06-scFv mice, and in particular, a greater enrichment of lymphocytes, especially T but also B cells (Extended Data Table 3 ). The proportions of CD4 + and CD8 + T cells in the blood, periaortic lymph nodes and spleens of Ldlr −/− and Ldlr −/− E06-scFv mice were not different (data not shown). There were no differences between the two groups in red blood cell or white blood cell counts, or in blood coagulation markers including prothrombin time (PT) and activated partial thromboplastin time (aPTT), fibrinogen and plasminogen (data not shown).
Recent genetic data demonstrate a strong causal role for Lp(a) and its associated OxPL in the aetiology of calcific aortic valve disease in humans 14, 19 . We therefore prospectively used M-mode two-dimensional and Doppler ultrasound, to measure gradients at the aortic valves in HCD-fed Ldlr −/− and Ldlr −/− E06-scFv mice at 6, 9 and 12 months, and at 15 months the calcium content of the aortic valves was evaluated histologically. There was a progressive increase over time in mean aortic valve pressure gradients in Ldlr −/− mice, consistent with early restriction of blood flow through the aortic valve, which was significantly attenuated in the Ldlr −/− E06-scFv mice and was 49% lower at 12 months ( Fig. 4a , Extended Data Fig. 6a and Extended Data Table 4 ). Total aortic valve calcium content was also significantly reduced by 41.5% (Fig. 4b, c ). Consistent with the more extensive pathology noted in the aortic valve leaflets in the Ldlr −/− mice ( Fig. 4b and Extended Data Fig. 5a ) representative M-mode echocardiography demonstrated thicker aortic valve leaflets in the Ldlr −/− mice (Extended Data Fig. 6b ). Over 15 months of prospective observation, it was notable that 6 out of 13 Ldlr −/− mice died, whereas 0 out of 10 Ldlr −/− E06-scFv mice died (P = 0.016, Kaplan-Meier survival analysis; Fig. 4d ).
Livers of mice on a HCD are known to develop steatosis and accumulate increased levels of oxidation-specific epitopes, including OxPL 20 . Livers from Ldlr −/− mice stained prominently with E06 IgM compared to Ldlr −/− E06-scFv livers ( Fig. 4f ), although hepatocyte-derived E06-scFv may partially mask OxPL epitopes in the livers of Ldlr −/− E06-scFv mice. The histological appearance of steatosis in the Ldlr −/− E06-scFv livers was decreased, which was confirmed by significant decreases in hepatic triglyceride and cholesterol content (Fig. 4e ), and there was decreased inflammatory gene expression in whole-liver extracts (Extended Data Fig. 6c ).
Serum amyloid A is known to be raised by cholesterol feeding and reflects a systemic inflammatory status in mice 21 . Notably, despite plasma cholesterol values of more than 800 mg dl −1 , plasma serum amyloid A levels were reduced by 32% in Ldlr −/− E06-scFv mice (P = 0.016) supporting a generalized decrease in systemic inflammation ( Fig. 4g ). Ldlr -/-E06-scFv (n = 11)
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Ldlr -/-Ldlr -/-E06-scFv Ldlr −/− E06-scFv mice (n = 7-11, as indicated in c). Compared to Ldlr −/− mice, atherosclerosis was significantly reduced in Ldlr −/− E06-scFv mice at 4, 7 and 12 months (en face sections, 57%, 34% and 28%; aortic root, 55%, 41% and 27%, respectively).
The detailed cellular and molecular mechanisms by which OxPL mediate these proatherogenic and proinflammatory effects are likely to be complex, dependent on the diverse OxPL and different cellular targets involved. For example, OxPL can activate cells by a variety of receptors, including CD36, TLR2-TLR1 and TLR2-TLR6, TLR4, CD14 and combinations of these receptors, and in turn, generate a wide variety of responses 1, 5, 7, 8, 16, [22] [23] [24] [25] . In addition, the phosphocholine on OxLDL mediates macrophage uptake by CD36 and SR-B1 5 . Presumably, extracellular E06-scFv binds to many of the extracellular OxPL moieties that are formed and by blocking uptake of OxLDL and inhibiting inflammatory signalling, contributes to reduced atherogenesis, although we cannot exclude the possibility that E06-scFv in the intracellular signalling pathway of macrophages or hepatocytes may also contribute in some manner.
In summary, we present a mouse model that demonstrates that, in the context of hypercholesterolemia, OxPL are involved in the pathogenesis of inflammation in general, and atherosclerosis, calcific aortic valve disease and hepatic steatosis specifically. Calcific aortic valve disease is a growing problem in our ageing population and leads to symptomatic aortic stenosis requiring aortic valve replacement by surgical or transaortic valve approaches in more than 2% of people over the age of 65 26 . Similarly, OxPL may be involved in the pathogenesis of NASH, which currently afflicts a high percentage of the population and increases the risk for cirrhosis and cardiovascular disease. The E06-scFv transgenic mice can be used to study the mechanisms by which OxPL contributes to these disease processes in vivo, as well as other disease states in which OxPL may have a role. For example, we recently demonstrated with these mice that OxPL restrain bone formation in mice fed either a Western or chow diet 27 .
This unique sensitivity of E06 to molecules with abnormally presented phosphocholine may allow specific therapeutic targeting of diseased tissues but not normal tissues in a variety of inflammatory states. As shown here as proof-of-principle, diseases of systemic inflammation that generate OxPL may be targets of OxPL-directed therapies. Furthermore, Aortic Macrophage uptake of AlexaFluor-488-OxLDL (%)
Fold change (log 2 ratio of RPKM) 
OxPL in various tissues can be imaged with OxPL-specific antibodies, such as in atherosclerotic aortas using magnetic resonance imaging-based nanoparticles 28 , which could aid in the appropriate selection of high-risk patients. The E06-scFv expressed in these mice lacks the Fc effector functions of antibodies, and therefore, its impact was caused solely by blocking biological effects of OxPL. Translational applications of E06 or similar anti-OxPL antibodies to humans, as well as antibodies to other oxidation-specific epitopes 29,30 , in which more traditional IgG isotypes are more likely to be used, will need to decipher any potential additional roles of various Fc effector functions. Ldlr Competing interests X.Q., S.T. and J.L.W. are co-inventors and receive royalties from patents owned by the University of California San Diego on the use of oxidation-specific antibodies. S.T. currently has a dual appointment at UCSD and as an employee of Ionis Pharmaceuticals. J.L.W. is a consultant to Ionis Pharmaceuticals. 
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Antigen preparation and modifications. Plasma was obtained from healthy donors after an overnight fast following consent under a protocol approved by the UCSD Human Research Protections Program. LDL was isolated by sequential ultracentrifugation, and modified with malondialdehyde (MDA), malondialdehyde-acetaldehyde adducts (MAA) or CuSO 4 to generate MDA-LDL, MAA-LDL or copper-oxidized LDL (Cu-OxLDL), respectively, as previously described 31 .
Phosphocholine-BSA (PC-BSA) was from Biosearch Technologies and POVPC-BSA was prepared as described 32 . Monoclonal anti-Myc and anti-His alkaline phosphatase-conjugated antibodies were from Sigma-Aldrich. E06-scFv construction and optimized expression. In the Supplementary Information, we describe in detail the history of the discovery of the IgM natural antibody E06/T15 and its binding specificity and biological properties. The cDNAs encoding the E06 variable heavy and light regions were connected with an oligo linker peptide of 15-amino acids (Gly 4 Ser) 3 that were assembled by overlapping PCR and cloned into an expression vector (pSecTag2A (Invitrogen)), which contains a mouse Igκ-chain leader sequence for secretion and Myc and polyHis tags that facilitates purification and detection. HEK293 cells (obtained from ATCC, mycoplasma not tested recently) were transfected with the pSecTag2A-E06-scFv plasmid using Lipofectamine plus (Invitrogen). Stable transfectants were selected with zeocin, and the E06-scFv antibody in the culture supernatant was identified using an ELISA plate pre-coated with Cu-OxLDL or PC-BSA and detection by anti-Myc or anti-His tag antibody conjugate using chemiluminescent assay techniques described previously 29 . During development, multiple linkers were tried and in addition, site-directed mutagenesis in framework region 1 was performed at seven sites in an iterative fashion using a QuickChange Multi Site-Directed Mutagenesis Kit (Stratagene) to create point mutations to improve the folding, stability, yield and reduce the aggregation of recombinant scFv. His6-tagged E06-scFv was purified on Ni-NTA agarose beads (Qiagen) according to the manufacturer's protocols.
In brief, cell lysates were clarified by centrifugation (20,000g, 30 min, 4 °C), and the supernatant applied to a Ni 2+ -NTA agarose column, from which His6-tagged E06-scFv was eluted with 250 mM imidazole. Fractions containing E06-scFv were pooled and extensively dialysed against PBS before use. The purity and integrity were assessed by SDS-PAGE and western blot with anti-His6-tag antibody-HRP conjugate, and an ECL detection system (Amersham). Generation of E06-scFv transgenic mice. The liver-specific expression vector pLiv7 was used to generate transgenic mice expressing the E06-scFv transgene driven by the Apoe promoter, as previously reported 33 . The MfeI-MluI fragment from the pSecTag2A-E06-scFv plasmid including the mouse Igκ leader sequence and Myc/His tags was released by MfeI and MluI digestion, and inserted into the polylinker region of pLiv7 to generate a transgenic vector pLiv7-E06-scFv. The Apoe-E06-scFv transgene consists of 3.0-kb Apoe promoter + N-terminal UTR of Apoe gene + E06-scFv transgene + C-terminal UTR of Apoe gene and a 0.77-kb hepatic control element (LE6) placed downstream of poly(A) signal ( Fig. 1) . To create transgenic mice, a 6.8-kb Apoe-E06-scFv transgene cassette was separated from the vector by digestion with SacII and SpeI, purified, and injected into the pronuclei of fertilized mouse eggs obtained from superovulated female mice (C57BL/6). The injected eggs were surgically transferred to oviducts of surrogate C57BL/6 females in the UCSD Transgenic and Knockout Mouse Core. Production and screening of transgenic mice. Offspring were screened for plasma E06-scFv titre and integration of the transgene by PCR amplification of the tail DNA with the upstream primer sequence MfeFw 5′-TACAATT GAGCTGGCTAGCCACCATGGAG-3′ and the downstream E06Rev3 primer sequence 5′-GCTGTACCAAGCCTCCTCCAGACTCCACC AG-3′ to yield a 540-bp product corresponding to the nucleotide sequence between −15 and 525 of E06-scFv cDNA. Mice from the highest expressing transgenic E06-scFv founder lines were bred with each other to generate 'homozygous' transgenic mice, and in turn, these were crossed into Ldlr −/− and Ldlr −/− Rag1 −/− mice, all on the C57BL/6 background. All animals were genotyped for E06-scFv and Ldlr −/− and plasma assayed to confirm expression of the E06-scFv by immunoassay. Binding profile of plasma E06-scFv quantified by chemiluminescent ELISA. E06-scFv plasma titres were determined by chemiluminescent ELISA assays for binding to phosphocholine epitopes as expressed on Cu-OxLDL, phosphocholine-KLH, PC-BSA, POVPC-BSA, and capsular polysaccharide (C-PS) of Streptococcus pneumonia, as well as to the anti-T15 idiotype antibody AB1-2 2 . Competition immunoassays were performed to demonstrate specificity 31, 32 . In brief, 96-well round-bottom MicroFluor plates (DYNEX Technologies) were coated with various antigens at 5 μg ml −1 (50 μl per well) in PBS overnight at 4 °C. After the plates were washed and blocked with 1% BSA in Tris-buffered saline (TBS) for 30 min, 25 μl of primary antibodies diluted with 1% BSA in PBS were added to the wells, in the absence or presence of competitors and incubated for 90 min at room temperature. Bound antibodies were detected with anti-His6-tag antibody conjugated to alkaline phosphatase (Sigma-Aldrich), in TBS buffer containing 1% BSA, followed by a rinse with water and the addition of 25 μl of 50% LumiPhos 530 (Lumigen) as luminescent substrate. The light emissions were measured, and counts expressed as relative light units over 100 ms using a Dynex Luminometer (DYNEX Technologies). For competition immunoassays, data are expressed as B/B 0 , were B represents binding in presence and B 0 in absence of competitors. In separate experiments, the absolute plasma E06-scFv levels in transgenic mice were determined using a standard curve generated with purified His6-tagged E06-scFv isolated as described above. All determinations were done in triplicate. Flow cytometry and deconvolution microscopy of E06-scFv mouse plasma binding to apoptotic cells. Plasma of Ldlr −/− E06-scFv and Ldlr −/− control mice were analysed for binding to apoptotic cells by flow cytometry (FACS) analysis as described 4 . Thymocytes collected from C57BL/6 mice were cultured in cell culture medium and induced to undergo apoptosis by 10 ng ml −1 PMA (Sigma-Aldrich) for 16 h. Plasmas diluted in 1% BSA in PBS were incubated with apoptotic thymocytes for 1 h at 4 °C, followed by incubation with a FITC-labelled anti-His6 monoclonal antibody in 1% BSA in PBS for 30 min at 4 °C. Apoptotic cells were double-stained with annexin V-phycoerythrin (annexin V-PE) and 7-amino-actinomycin (7AAD) (BD Biosciences) for 15 min and immediately analysed by FACS using a FACSCanto (BD Biosciences). For immunofluorescence microscopy studies, apoptotic Jurkat cells were prepared by exposure to UV irradiation at 20 mJ cm −2 , and further cultured for 16 h before use. Apoptotic Jurkat cells (from ATCC, mycoplasma not tested recently) were incubated with 100 μl of plasma (1:20) in 1% BSA in PBS at 4 °C for 1 h, washed and labelled with a FITC-conjugated anti-His6-tag monoclonal antibody (1:1,000) and 1 μg ml −1 of Hoechst dye (Sigma-Aldrich) for 45 min at 4 °C. The cells were fixed with 3.7% paraformaldehyde for 20 min, washed and resuspended in 1% BSA in PBS. The cells were spun down on glass slides using cytospin (Thermo Shandon). Images were captured using a DeltaVision deconvolution microscopic system operated by SoftWorx software (Applied Precision).
Demonstration of specificity of E06-scFv binding to OxPL and ability to inhibit
OxLDL binding to macrophages. Binding of biotinylated OxLDL to J774 macrophages plated in microtitre wells was assessed by a chemiluminescent binding assay as described recently 34 . In brief, biotinylated Cu-OxLDL (5 μg ml −1 ) was incubated overnight in the absence or presence of E06-scFv-Tg plasma or control at various dilutions at 4 °C. The supernatants were then added to macrophages plated in 96-well microtitre plates and the binding of biotinylated OxLDL detected by alkaline phosphatase-labelled NeutrAvidin and chemiluminescent ELISA. For each study, we sought to have 8−10 mice per group, which based on experience would be sufficient to detect differences in atherosclerosis. The identify of the mice was not blinded during the HCD feeding period, but determination of atherosclerosis, the outcome of the study, was done in a blinded fashion. Blood samples were collected from submandibular bleeding at time 0, and various time points on diet. Mice were weighed monthly, and total cholesterol and triglycerides levels were determined using automated enzymatic assays (Roche Diagnostics, Indianapolis). Lipoprotein profiling was performed on terminal blood samples using fast performance liquid chromatography equipped with a Superose 6 column, and total cholesterol and triglycerides levels in each fraction were determined as previously described 29 .
Effect of E06-scFv on atherosclerosis in Ldlr
Bone marrow transplantation study. Bone marrow transplantation (BMT) was performed as previously described 35 . In brief, bone marrow was collected from cleaned femurs and tibias of male E06-scFv mice (not on a Ldlr −/− background) and wild-type C57BL/6 mice and re-suspended in RPMI 1640 medium for injection. Ldlr −/− male recipient mice were fasted overnight and received a lethal dose of radiation (9 Gy) 4 h before bone marrow injection. Mice (n = 13 per group) were anaesthetized with isoflurane, and 5 × 10 6 bone marrow cells either from E06-scFv mice or from C57BL/6 wild-type mice were injected into the retro-orbital venous plexus. Three days before and two weeks after the BMT, recipient mice received autoclaved acidified (pH 2.7) water supplemented with 100 μg ml −1 neomycin and 10 μg ml −1 polymyxin B sulphate. Two weeks after BMT, all mice were given a Western diet (TD00457, Harlan) for 16 weeks to induce atherosclerosis. Reconstitution of transplanted bone marrow was confirmed based on titres of E06-scFv secretion in plasma. Atherosclerosis analysis. Mice exposed to a HCD or Western diet were euthanized using 100% CO 2 . Sections of spleen, kidney and liver tissues were frozen in RNAlater solution (Ambion) for mRNA extraction or embedded in OCT (Sakura Tissue-Tek) for cryosectioning. After perfusion with 4% formalin-sucrose for 15 min, livers and hearts were removed, fixed and embedded in paraffin and serially sectioned. The aortas were dissected under a microscope and fixed in 4% formalin-sucrose, opened, flattened pinned and stained with Sudan IV, and images of the aortas were captured and quantified by analysis of the entire en face aorta Letter reSeArCH as previously described 35 . Aortic root cross-sectional lesion areas were quantified using serial cross-sections taken at 100-μm intervals between 100 μm and 900 μm beginning with the first appearance of the first leaflet of the aortic valve until the last leaflet. Mean lesion size at each 100-μm section in each animal was determined by computer-assisted morphometry (Image-Pro Plus 6.3, Media Cybernetics) on serial 10-μm paraffin sections. Modified van Gieson elastic stain was used to enhance the contrast between the intima and surrounding tissue. Cross-sectional plaque area and plaque morphology were evaluated by two investigators blinded to the study protocol. The results are presented as mean of all values for each interval plotted versus the distance from first leaflet and the overall extent of aortic root lesions was determined by area under the curve (AUC) analysis of all serial sections in each group.
In lesions of the four-month HCD experiments, we also determined the area of necrosis by computer-assisted morphometric analysis of extent of necrosis of five lesions taken at each 100-μm interval and expressed as the absolute area involved at that site. In the seven-month experiment, lesions on each of the 100-μm sections were selected to be of equal total size between the Ldlr −/− and Ldlr −/− E06-scFv aortic sections at that level, and the area of necrosis determined and plotted at each 100-μm section. For both the four-and seven-month analyses, the extent of necrotic area was determined as the AUC analysis of all serial sections in each group. Echocardiographic and histological analysis of aortic valve. Ldlr −/− (n = 13) and Ldlr −/− E06-scFv (n = 10) mice were fed a HCD for 15 months and aortic valve function was serially evaluated with Doppler ultrasound, 2D and M-mode echocardiography at 6, 9 and 12 months. At 15 months, the extent of atherosclerosis was determined and aortic valves evaluated histologically. A Kaplan-Meier survival analysis was also performed on the entire cohort. Severity of aortic sclerosis was determined quantitatively by calculating peak pressure gradients across the aortic valves using Doppler analysis and measurement of aortic valve leaflet thickness using M-mode echocardiography. Pressure gradients were determined from aortic blood flow velocities (V) using the principles of conservation of energy and calculated by the modified Bernoulli equation (∆P = 4(V aorta 2 − V LVOT 2 )) 9 . Images were acquired using high-resolution (32-55 MHz) ultrasound (VisualSonics Vevo 2100) as previously described 36 . Histological assessment of aortic valves was determined on serial sections at 100-μm intervals from the origins of the aortic valve leaflets at the base of the aortic root, and stained for calcium using Von Kossa's method. Calcium on each section was quantified by number of pixels 'stained' using ImageJ software. Total aortic valve calcium was determined by AUC analysis of all serial sections in each group.
Immunohistologic analyses of atherosclerotic lesions and liver tissues.
Immunohistochemical studies were performed on sections of paraformaldehyde-fixed and paraffin-embedded tissues. Paraffin sections of atherosclerotic lesions, aortic roots and liver tissues were stained for OxPL with biotinylated E06 IgM, or with E06-scFv using a biotinylated monoclonal antibody anti-Myc tag (Miltenyi Biotech) following the manufacturer's instructions. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in PBS for 15 min. After blocking, non-specific binding sites with 10% normal goat serum and Fc Block (2.4G2 antibody) in PBS for 30 min, slides were incubated with primary antibodies for 1 h at room temperature. Biotinylated antibodies (E06, anti-Myc and anti-polyHis) were revealed with ABC-HRP VectaStain kit (Vector Laboratories, Burlingame, California) and/or NovaRed substrate (Vector Labs). Slides were counterstained by haematoxylin and in some experiments, percentage of positively stained targets were quantified by image analysis morphometry (Image-Pro Plus). Determination of cellular composition of aorta. Cellular composition of aortas was determined in the Cell Phenotyping Core of the UCSD PPG on Role of Immune Mechanisms in Inflammation and Atherosclerosis, under the direction of K.L., using established techniques 37 . In brief, six aortas from 16-week chowfed Ldlr −/− , six from HFD-fed Ldlr −/− and five from Ldlr −/− E06-scFv mice were dissected following heparin PBS perfusion and adventitia were carefully removed. The intact aortas were incubated for 1 h with an Aorta Dissociation Enzyme stock solution and single-cell suspensions were prepared from the digested aorta by shearing the aortas apart and passing cells through a 70-μm cell strainer into 5-ml polypropylene FACS tubes (BD Falcon). The cells were pelleted by centrifugation (400g, 5 min, 4 °C), resuspended in 1 ml of FACS buffer (PBS supplemented with 1% BSA and 0.05% NaN 3 ), counted and assessed for viability using trypan blue in a haemocytometer. Cells were stained on ice for 30 min with the panel of antibodies below, washed twice with FACS buffer and then analysed at La Jolla Institute for Allergy and Immunology using a FACSAria analyser. Anti-CD45 antibody and fixable live-dead cell stain (Invitrogen, Molecular Probes) was added to all samples to allow for gating of live CD45 + leukocytes and cells were sorted with the panel of antibodies listed in in Supplementary Table 1 . Analysis of T cells in blood, spleen and periaortic lymph nodes by flow cytometry. Blood from Ldlr −/− or Ldlr −/− E06-scFv mice was collected in 4% sodium citrate solution. Blood lymphocytes were obtained from the interface after underlying and spinning the blood with Histopaque 1077 (Sigma-Aldrich). Periaortic lymph nodes and spleens were processed to obtain single-cell suspensions. Spleen samples were lysed with 1× RBC lysis buffer (BioLegend). Cell suspensions were counted using a Z2 Coulter counter (Beckman Coulter) to obtain absolute numbers of each cell population. Single-cell suspensions were stained as routinely done in our laboratory 38 , with antibodies against CD4 (clone RM4-5; Life Technologies), CD8 (clone 53-6.7; Biolegend), TCRβ (periaortic LNs and spleen only) (clone H57-597; eBioscience), CD44 (clone IM7, Biolegend), CD25 (clone PC61, Biolegend) and live/dead exclusion yellow dye (Life Technologies) in FACS buffer (2% BSA in PBS). Cells were stained on ice for 30 min, washed twice with FACS buffer and then samples were analysed using LSRII (BD Bioscience). Data were analysed using FlowJo 9.7 (Tree Star Inc.). RNA analysis of tissues. Total RNAs were extracted from individual frozen tissue samples (livers) or TGEM using RNeasy mini kit (Qiagen) as per the manufacturer's instructions. Tissues were homogenized in RNeasy lysis buffer with a motorized homogenizer. Genomic DNA was removed by DNase I, and RNA concentration and quality were assessed with by NanoDrop. Next, 1 μg of RNA was reversely transcribed to cDNA using EcoDry Premix kit (Clontech). Real-time qPCR was carried out to determine gene expression of inflammatory molecules. All reactions were performed in the Rotor-Gene Q cycler (Qiagen) in triplicates using 50 ng of cDNA and qPCR Master Mix (Eurogentec), primers and Taqman fluorescent probes (Applied Biosystems) in a total reaction volume of 20 μl. Relative quantities of mRNA were calculated using ΔΔC t formula and two standard curves relative quantitation using Rotor-Gene Q Software 1.7 (Qiagen) with Gapdh as the reference gene. Analyses of peritoneal macrophages. Thioglycollate-elicited peritoneal macrophages (TGEM) from Ldlr −/− and Ldlr −/− E06-scFv-Tg mice fed a HCD diet for five weeks were isolated three days after intraperitoneal injection of 1 ml of 2% thioglycollate broth (Sigma-Aldrich) as previously described 13 . TGEM were collected for RNA-sequencing analysis, cholesterol analysis and mass spectrometry determinations of sterols as previously described 18 . TGEM were isolated from three mice in each group and each set of macrophages divided into two separate aliquots, which were individually extracted and sterols determined in triplicate by liquid chromatography-tandem mass spectrometry following LipidMaps protocols online at http://www.lipidmaps.org/.
In other studies to assess the ability of macrophages to secrete the E06-scFv, TGEM were obtained from E06-scFv-Tg mice plated at a density of 5 million cells per well in 6-well plates in 10% FBS in RPMI. On day 4, cells were incubated with T0901317 at 10 μM ml −1 (or vehicle) in 1% delipidated, charcoal-stripped FBS in RPMI. Cell-culture supernatants were concentrated and assessed for E06-scFvbinding activity by ELISA. Cell pellets were checked for expression of E06-scFv by qPCR.
RNA-sequencing analysis was performed on TGEM from four biological replicates. Total RNAs were converted into cDNA libraries as templates for high-throughput sequencing using Illumina HiScanSQ or HiSeq2500 following the Illumina TruSeq RNA sample preparation protocol. In brief, first-strand cDNA was synthesized from 5 μg of total RNA using oligo-dT primers and EcoDry Premix kit (Clontech) for cDNA synthesis, and subsequently converted into blunt ends via exonuclease/polymerase. After adenylation of 3′ ends of DNA fragments, Illumina PE adapters were ligated to prepare cDNA fragments of preferentially 200 bp in length and enriched using Illumina PCR primers in a 15-cycle PCR reaction. After cluster generation, 100-bp paired-end reads were generated and analysed by alignment to the UCSC mouse reference genome using TopHat/Bowtie. The numbers of reads mapping to exonic and intronic regions as well as to splice sites were calculated based on the UCSC annotation file. Reads per kilobase of exon model per million mapped reads (RPKM) values for Refseq genes were established. RNA-sequencing clusters were analysed by Cuffdiff2, TreeView6, for heat map, and DAVID6.7 to determine differential gene expression (DEG) between Ldlr −/− and Ldlr −/− E06-scFv macrophages, and by Gene Ontology classification to assign gene changes to different functional categories. For statistical analysis of DEG, the Cufflinks data of P values from the t-tests of RPKM in RNA-sequencing data were further analysed using R packages (DEseq2) from Illumina BaseSpace Sequence Hub and converted to FDR-adjusted Q values. The concise output files included only those transcripts that have a Q value lower than the given FDR, and the value of the significant column was adjusted accordingly (yes/no) in all output files. All DEG values shown are FDR-corrected P < 0.05. Determination of uptake of fluorescent OxLDL by peritoneal macrophages in vivo. Rag1 −/− mice lack T and B cells and plasma antibodies. Rag1 −/− Ldlr −/− mice and Rag1 −/− Ldlr −/− E06-scFv transgenic mice (which only have E06-scFv antibodies) were injected intraperitoneally with 1 ml of sterile 2% thioglycollate to induce sterile peritonitis. Four days later, the mice were injected intraperitoneally with 100 μg of AlexaFluor-488-labelled OxLDL in 200 μl PBS per Ldlr −/− mouse 39 . The mice were euthanized 1 h after injection, and peritoneal cells were recovered by lavage with 10 ml of ice-cold PBS containing 1% heat-inactivated FBS and 10 mM
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Extended data table 3 | Cell counts of viable aortic cells determined using FACS analysis
Cell counts of viable aortic cells isolated from aortas of chow-fed and HCD-fed Ldlr −/− mice and HCD-fed Ldlr −/− E06-scFv mice. Values are mean ± s.d. of total viable cells evaluated by flow cytometry per aorta as described in the Methods. Number of aorta for each group: n = 5 HCD-fed Ldlr −/− E06-scFv mice; n = 6 chow-fed Ldlr −/− mice and n = 6 HCD-fed Ldlr −/− mice. *Note that one aorta from one HCD-fed Ldlr −/− mouse had extensive atherosclerosis and had 27,846 viable cells counted. The next highest value in this group was 9,342. By comparison, the highest in the Chow-fed Ldlr −/− group was 2,909 and in the HCD-Ldlr −/− E06-scFv group was 5,692. Aortic cells were evaluated by flow cytometry as described in the Methods. Data for phenotypes of monocyte/ macrophages are shown in Fig. 3 A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Data Availability: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. The raw sequence data presented in this article have been submitted to the National Center for Biotechnology Information Sequence Read Archive (https:// www.ncbi.nlm.nih.gov/sra/, BioProject) under accession number PRJNA438959.
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Study design
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Sample size
For various atherosclerosis studies, sample sizes were selected based on many years of experience; roughly 10-13 mice per experimental group were used: we conducted 5 separate studies over 3 years and so results involve > 100 mice in total and we feel results are robust. For other experiments, biological replicates were of size to provide confidence in measurements. Numbers of mice used in each experiment are recorded in figures and/or legends Data exclusions For the experiments, the data are reported in full. In the roughly 100+ mice studied in the various atherosclerosis studies, we found one mouse that had a bicuspid aortic valve and there was enhanced lesion around this but as this was a rare and single event, we did exclude this one mouse. Not mentioned in Methods or results as such a rare event. All other data are defined in Legends of each experiment.
Replication
The number of mice studied, or number of biological observations studied for each experiment are provided in figures or legends in every case.
Randomization For atherosclerosis studies, Ldlr or Ldlr/E06-scFv-Tg mice were matched for age/sex (male) and baseline cholesterol for each of the studies.
Blinding
For the main findings: the analysis of extent of atherosclerosis or the changes in flow dynamics across the aortic valve--were done in blinded fashion by those who performed these analyses.
Materials & experimental systems
Policy information about availability of materials n/a Involved in the study
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Unique materials
Obtaining unique materials There are no unique reagents available only to us. The E06 antibody is commercially available now (see below). We made the E06-scFv transgenic mice --which are unique--and will make them available to interested investigators in the future.
Antibodies
Antibodies used All antibodies used are described in Materials and Methods. The IgM E06 is now available from Avanti Polar Lipids. The manuscript describes in detail the generation of the E06-scFv and its validation. Arrangements are being made to have Avanti generate and make available the E06-scFv as well.
Validation
Aside from the E06 antibody, which has been extensively characterized in the literature as described in Supplemental Information, the antibodies used in the FACS analysis are all listed in the Methods or in Supplemental Information. Antibody
